The pivotal role of CD8+ T cells in antitumor effect elicited by anti-TIM-3/CD137 mAb treatment is consistent with other combined strategies involving anti-CD137 mAb, such as combined cyclophosphamide/anti-CD137 treatment [33], which has been shown to produce synergist antitumor effects via expansion of CD8+ tumor-specific T cells. The gene discussed is TNFRSF9; the disease is neoplasm.